Security key
03969K108
Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT)
CUSIP: 03969K108
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 125,804,940
- Total 13F value
- $2,370,184,094
- Share change
- -1,298,888
- Put/Call ratio
- 33%
- SEC-reported price per share
- $18.85
- Number of holders
- 235
- Value change
- -$12,772,142
- Number of buys
- 117
- Number of sells
- 104
- Shares outstanding
- 123,454,843
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
235
Top holders
10
ARQT full security history
Ownership snapshot
Full 13F holder table
Arcutis Biotherapeutics, Inc. SEC filings
Arcutis Biotherapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ARQT - Arcutis Biotherapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences VII...
Disclosed value leader
SUVRETTA CAPITAL MANAGEME...
Comparable rows
15/15
Latest evidence
18 Aug 2025
13D/G
3/4/5
13F
Lead comparable stake: 7.5%
13D/G row: Frazier Life Sciences VIII, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Frazier Life Sciences VIII, L.P. leads the comparable SEC ownership view at 7.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences VIII, L.P.'s linked filing trail.
Comparable ownership
Top 5
Frazier Life Sciences VIII, L.P.
7.5%
Polar Capital Holdings Plc
4.2%
SUVRETTA CAPITAL MANAGEMENT, LLC
9.3%
JENNISON ASSOCIATES LLC
9%
Rubric Capital Management LP
8.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences VIII, L.P. |
13D/G
3/4/5
Patrick J. Heron · 10%+ Owner
|
7.5%
|
$130,399,321
8,943,712 shares
|
$0 | 18 Aug 2025 |
| Polar Capital Holdings Plc |
13D/G
13F
Company
|
4.2%
|
$75,147,145
5,006,472 shares
|
-$25,517,045 | 30 Jun 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
Company
|
9.3%
|
$161,728,860
11,535,582 shares
|
— | 30 Jun 2025 |
| JENNISON ASSOCIATES LLC |
13F
Company
|
9%
|
$155,753,857
11,109,405 shares
|
— | 30 Jun 2025 |
| Rubric Capital Management LP |
13F
Company
|
8.7%
|
$150,707,387
10,749,457 shares
|
— | 30 Jun 2025 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
8%
|
$138,440,644
9,874,511 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
235
Shares
125,804,940
Rows available
235
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
228
Q3 2025 holders
235
Holder diff
7
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|